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Abstract
Background: Whether phosphate itself has nephrotoxicity in patients with chronic kidney disease (CKD) is
controversial, although phosphate excretion into urine may cause tubular damage in rat models. To evaluate actual
phosphate load on each nephron, we examined the association between 24-h urinary phosphorus excretion per
creatinine clearance (24-h U-P/CCr), a newly proposed index that is a surrogate for nephron load, and CKD
progression in patients with CKD.
Methods: We conducted a single-center, retrospective cohort study. To avoid potential confounders for protein
intake, only patients on our educational program for CKD with a fixed diet regimen and aged 20 years or older
were included. The observation period was 3 years. Primary outcomes were CKD progression defined as a
composite of end-stage kidney disease (ESKD) or 50 % reduction of estimated glomerular filtration rate. Patients
were stratified by quartiles of 24-h U-P/CCr levels as Quartiles 1–4. The association was examined in three models:
unadjusted (Model 1), adjusted for risk factors for CKD progression (Model 2), and factors that affect renal
phosphate handling (Model 3).
Results: A total of 191 patients met the eligibility criteria. Patients with higher 24-h U-P/CCr showed a higher risk
for the composite outcomes. The hazard ratios [95 % confidence interval] for 24-h U-P/CCr levels in Quartile 2, 3,
and 4, respectively, versus Quartile 1 were 2.56 (1.15–6.24), 7.53 (3.63–17.62), and 12.17 (5.82–28.64) in Model 1; 1.66
(0.63–4.97), 3.57 (1.25–11.71), and 5.34 (1.41–22.32) in Model 2; and 3.07 (0.97–11.85), 7.52 (2.13–32.69), and 7.89
(1.74–44.33) in Model 3.
Conclusions: Our study showed that higher phosphorus excretion per creatinine clearance was associated with
CKD progression.
Keywords: Collected urine, Chronic kidney diseases, End-stage kidney disease, Bone diseases, Metabolic, Protein
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Background
Serum phosphorus level is a risk factor for cardiovascu-
lar disease in patients with chronic kidney disease
(CKD) [1–3]. Several studies also reported that higher
serum phosphorus levels were associated with CKD pro-
gression [4, 5]. Meanwhile, there is considerable evi-
dence that serum phosphorus level is dependent on
protein intake [6]. Renal phosphate handling is affected
by phosphate loading and depletion, parathyroid hor-
mone, 1,25-dihydroxyvitamin D (1,25(OH)VitD)‚ vol-
ume, hyper- and hypocalcemia, glucose, acid–base
disturbance, dopamine, and fibroblast growth factor
(FGF)-23 [7]. Of these, parathyroid hormone and FGF-
23 have been considered as especially important factors
that regulate renal phosphate handling [8]. Although the
mechanism between high serum phosphorus and CKD
progression is not fully elucidated, it is assumed that
phosphate excretion into urine causes tubular damage.
The degree of kidney damage depends not only on the
amount of phosphate load but also the nephron number
[9], while tubular damage occurred in rats when phos-
phate excretion per nephron exceeded 1 μg/day [10]. To
evaluate actual phosphate burden on residual nephrons,
we proposed a new index, 24-h urinary phosphorus ex-
cretion per creatinine clearance (24-h U-P/CCr), as a
prognostic factor for CKD progression. In animal stud-
ies, renal biopsy and magnetic resonance imaging were
used to estimate glomerular number. A previous study
reported a positive correlation between glomerular filtra-
tion rate (GFR) and glomerular number in stable renal
transplants [11]. Thus, we used 24-h CCr as a marker for
nephron number. To avoid potential confounders for
protein intake, only patients on the educational program
for CKD with a fixed diet regimen were included. The
association between 24-h U-P/CCr and CKD progression
in these patients was examined.
Methods
Study population and outcomes
We conducted a single-center, retrospective cohort study
in a Japanese population to examine the association be-
tween 24-h U-P/CCr and CKD progression.
Patients aged 20 years and older who were admitted to
the hospital and who were in the educational program
for CKD between January 2001 and December 2006
were enrolled. A fixed amount of protein (0.6 to 0.8 g/
kg, standard body weight) was served to each patient
during the whole admission period. The proportion of
animal protein in the diet regimen was 50–60 % of the
total. Therefore, the phosphate intake of each patient
was also fixed at about 0.8 to 1.0 g/kg of standard body
weight. Patients with acute kidney injury or primary
hyperparathyroidism were excluded. Although the obser-
vation period was 3 years, patients who were lost to
follow-up were censored at the date of the last contact
with an attending physician of the hospital.
Data on age, weight, and sex of the patients, and co-
morbid conditions, including history of diabetes melli-
tus and laboratory data, were obtained by review of
medical records. Laboratory data included serum cre-
atinine (mg/dL), urea nitrogen (mg/dL), albumin (g/dL),
calcium (mg/dL), phosphorus (mg/dL), intact parathor-
mone (PTH) (pg/mL), 1,25(OH)VitD (pg/mL), CCr (ml/
min), 24-h urea nitrogen excretion (g/day), 24-h urinary
protein (g/day) and 24-h urinary phosphorus (mg/day).
Serum calcium concentration was corrected for serum
albumin concentration using the following formula:
Corrected calcium =measured calcium − (4 − serum al-
bumin) [12]. Estimated GFR (eGFR) was calculated
using the equation developed by the Japanese Society of
Nephrology to adjust for characteristics of Japanese patients
as follows: eGFR = 194 × serum creatine−1.094 × age−0.287 (if
female, × 0.739) [13]. Daily protein intake was estimated
using Maroni’s formula as follows: Estimated protein in-
take = (urea nitrogen excretion [g/day] + 0.031 [g/kg] ×
body weight [kg]) × 6.25) [14]. Because over 50 % of pa-
tients had no record about use of angiotensin receptor
blockers, angiotensin-converting enzyme inhibitors or
other drugs, or history of hypertension and heart disease
or smoking status, we did not include these factors as
variables.
The primary outcomes of this study were CKD pro-
gression defined as a composite of end-stage kidney
disease (ESKD) or 50 % reduction in eGFR. We com-
pared subgroups stratified by quartile of 24-h U-P/CCr
levels: ≤ 11.15 mg/day/CCr (Quartile 1), 11.16 to
17.07 mg/day/CCr (Quartile 2), 17.08 to 29.61 mg/day/
CCr (Quartile 3), and ≥ 29.62 mg/day/CCr (Quartile 4).
We also examined the association between 24-h U-P/CCr
and serum phosphorus. Associations were examined in
models with incremental multivariable adjustments: un-
adjusted (Model 1); comorbid conditions, and risk factors
for CKD progression such as age, male sex, diabetes, CCr,
protein intake, urinary protein, and corrected calcium
(Model 2); and factors that influence phosphate reabsorp-
tion such as age, male sex, CCr, protein intake, corrected
calcium, 1,25(OH)VitD, and PTH (Model 3). Unadjusted
and multivariable-adjusted relative risks for progressive
CKD in relation to 24-h U-P/CCr were calculated using
Cox proportional hazard models. The assumption of pro-
portional hazards in the Cox regression models was
assessed and found to be acceptable (Fig. 1).
To compare 24-h U-P/CCr with common markers of
urinary phosphorus excretion, we examined for the associ-
ation of fractional excretion of phosphorus (FeP), tubular
reabsorption of phosphate (TRP), and maximum tubular
reabsorption of phosphorus per unit volume of
glomerular filtration rate (TmP/GFR) with primary
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outcomes. TRP was calculated using the following for-
mula: TRP = 1 − (urinary phosphate × serum creatinine)/
(serum phosphate × urinary creatinine). We also analyzed
an alternate model, where 24-h U-P/eGFR, instead of
24-h U-P/CCr, was applied to a variable, because this is
more commonly used by Japanese physicians.
A total of 191 patients met the eligibility criteria. Of
these, one (0.5 %) patient had primary hyperparathyroid-
ism, eight (4 %) patients had evidence of acute kidney
injury and seven (3 %) patients had missing values, ex-
cluding them from analyses. 1,25(OH)VitD or PTH were
missing in 24 (15 %) patients, excluding them from ana-
lyses only in Model 3. The final analyses were carried
out in 175 patients in Model 1 and Model 2, and 151
patients in Model 3. Statistical analyses were performed
using JMP, version 11.2, (SAS Institute Inc., Cary, NC,
USA), and Excel-Toukei 2012 (Social Survey Research
Information Co., Ltd., Japan), where p < 0.05 was consid-
ered statistically significant.
Ethics
This study was approved by the ethics committee of JA
Toride Medical Center, and the research was performed
in accordance with the ethical principles of the Declar-
ation of Helsinki. According to the ethics committee of
JA Toride Medical Center, there was no need for patient
consent for this anonymous retrospective study.
Fig. 1 Proportional hazards with the applied predictors in the Cox model were assessed by plotting a negative logarithm of the Kaplan–Meier
Survivor estimate. The hazard ratio in each patient was calculated, and then patients were divided into two groups according to the median of
the hazard ratio. a Proportionality of hazards in Model 2 divided into high and low hazard. b Proportionality of hazards in Model 3, as in (b)
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Results
Baseline characteristics are shown in Table 1 for patient
groups stratified by 24-h U-P/CCr quartile. Mean age of
the studied population was 65 years, and 69 % were
male. Prevalence of diabetes mellitus was 34 %. Mean
eGFR was 19.1 ml/min/1.73 m2. The patients with CKD
stage G5 represented the largest population and there
was no patient with CKD stage G1. Patients with Quar-
tile 3 had lower protein intake, but when 24-h U-P/CCr
was included as a continuous variable, a significant stat-
istical correlation was not observed between 24-h U-P/
CCr and protein intake (Fig. 2a). Pearson’s correlation
coefficient (r) for this correlation was −0.03 (p = 0.66). In
contrast, a highly significant statistical correlation be-
tween urinary phosphorus and protein intake was ob-
served (r = 0.73, p < 0.001) (Fig. 2b). Fig. 3 shows that
24-h U-P/CCr was elevated earlier than serum phos-
phorus in CKD patients. Patients in Quartile 4 had lower
eGFR and corrected calcium and higher serum phos-
phorus, PTH and urinary protein.
The mean 24-h U-P/CCr was 20.9 ± 12.7 mg/day/CCr
and the median value was 17.07 mg/day/CCr. The max-
imum and minimum values were 53.97 mg/day/CCr and
3.95 mg/day/CCr, respectively. The first quartile value
was 11.15 mg/day/CCr, and the third quartile was
29.61 mg/day/CCr. A significant correlation was ob-
served between serum phosphorus and U-P/CCr in pa-
tients with CKD stage G5 (r = 0.68, p < 0.001), but not in
patients with CKD stage G3b (r = 0.09, p = 0.67) as
shown in Fig. 2c and d.
Median follow-up period was 1.56 year. Ninety (51 %)
patients reached the composite outcomes of ESKD or
50 % reduction of eGFR over 3 years, of whom 50
(29 %) reached ESKD and 40 (23 %) had a greater than
50 % reduction. More patients in Quartile 4 reached the
composite outcomes (Table 2).
The hazard ratio (HR) and 95 % confidence interval
(CI) of the composite outcomes in the unadjusted Cox
proportional hazard model and after adjustment are
shown in Table 3. Higher 24-h U-P/CCr was associated
with a higher risk for the composite outcomes in all
models. In Model 1, the HRs and 95 % CIs for Quartile
2, Quartile 3, and Quartile 4, respectively, with Quartile
1 as a reference were 2.56 (1.15–6.24), 7.53 (3.63–17.62),
and 12.17 (5.82–28.64). The corresponding values were
1.66 (0.63–4.97), 3.57 (1.25–11.71), and 5.34 (1.41–22.32)
Table 1 Baseline characteristics stratified by quartiles of urinary phosphorus per creatinine clearance
All Quartile 1 Quartile 2 Quartile 3 Quartile 4 P Value
(N = 175) ≤ 11.15 11.16–17.07 17.08–29.61 ≥ 29.62
(N = 44) (N = 44) (N = 43) (N = 44)
Age 65.4 ± 12.3 67.4 ± 14.1 66.9 ± 11.0 66.9 ± 9.64 61.1 ± 13.1 0.07
Male sex (n, %) 120 (68.5) 35 (79.6) 31 (70.5) 26 (60.5) 28 (63.6) 0.21
Body mass index 23.6 ± 3.58 23.2 ± 3.82 23.7 ± 3.75 23.1 ± 3.64 24.2 ± 3.07 0.44
Diabetes mellitus (n, %) 59 (33.7) 15 (34.1) 14 (32.6) 18 (32.6) 18 (40.9) 0.60
Protein intake (g/day) 36.8 ± 10.78 41.1 ± 13.7 35.0 ± 8.97 33.0 ± 9.00 37.9 ± 9.24 0.10
Cr (mg/dL) 3.73 ± 2.22 1.70 ± 0.56 2.68 ± 1.01 3.83 ± 1.13 6.71 ± 1.70 < 0.001
estimated GFR (ml/min/1.73 m2) 19.1 ± 13.5 35.3 ± 14.3 20.7 ± 7.34 13.0 ± 4.18 7.34 ± 2.77 < 0.001
CKD stage G2 (n,%) 4 (2.3) 4 (9.1) 0 (0.0) 0 (0.0) 0 (0.0)
G3a (n,%) 4 (2.3) 4 (9.1) 0 (0.0) 0 (0.0) 0 (0.0)
G3b (n,%) 26 (14.9) 21 (47.7) 5 (11.4) 0 (0.0) 0 (0.0)
G4 (n,%) 55 (31.4) 13 (29.5) 27 (61.4) 13 (30.2) 2 (45.5)
G5 (n, %) 86 (49.1) 2 (4.5) 12 (27.3) 30 (69.8) 42 (95.5)
24-h-CCr (ml/min) 24.7 ± 22.1 49.4 ± 28.7 24.7 ± 12.1 14.6 ± 5.93 9.83 ± 3.66 < 0.001
Corrected Ca (mg/dL) 9.41 ± 0.63 9.72 ± 0.44 9.57 ± 0.51 9.39 ± 0.51 8.96 ± 0.75 < 0.001
Serum phosphorus (mg/dL) 4.20 ± 1.07 3.50 ± 0.57 3.76 ± 0.58 4.19 ± 0.82 5.35 ± 1.14 < 0.001
iPTH (pg/mL) 139.0 ± 134.1 54.8 ± 27.8 95.7 ± 52.2 156.3 ± 114.3 261.5 ± 186.6 < 0.001
1,25(OH)VitD (pg/mL) 24.7 ± 22.1 36.9 ± 16.9 26.1 ± 10.9 22.0 ± 9.9 13.0 ± 6.1 < 0.001
Urinary protein (g/day) 2.15 ± 2.46 1.18 ± 1.98 1.86 ± 2.03 1.94 ± 1.93 3.63 ± 3.07 < 0.001
Urinary phosphorus (mg/day) 356 ± 158 393 ± 201 342 ± 163 310 ± 114 379 ± 129 0.06
Data are means ± SD or n (% of total), Comparisons were made by χ2 test or analysis of variance (ANOVA). Continuous variables were expressed as mean ±
standard deviation (SD), and categorical variables were expressed as proportions. Categorical variables were tested by χ2 test, and continuous variables were
compared by ANOVA. The homogeneity of the variances was analyzed by the Leven test; in those cases in which the variances were unequal, the variables were
compared by Welch’s test. Cr, serum creatinine levels; GFR, glomerular filtration rate; 24-h-CCr, 24-h creatinine clearance; Ca, calcium; iPTH, intact parathormone;
1,25(OH)VitD, 1,25 dihydroxyvitaminD
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Fig. 2 Bivariate fit plot. a Bivariate fit plot of protein intake by 24-h urinary phosphorus per creatinine clearance. b Bivariate fit plot of protein
intake by urinary phosphorus. c Bivariate fit plot of serum phosphorus by urinary phosphorus per 24-h creatinine clearance (24-h U-P/CCr) in
patients with CKD stage G3b. d Patients with CKD stage G5. r denotes Pearson’s correlation coefficient, p denotes p values for correlation, and
the ellipsoidal line indicates Bivariate Normal Ellipse where p = 0.95
Fig. 3 Association between urinary and serum phosphorus and eGFR. 24-h U-P/CCr, urinary phosphorus per 24-h creatinine clearance. 24-h U-P/
CCr denotes urinary phosphorus per 24-h creatinine clearance
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in Model 2, and 3.07 (0.97–11.85), 7.52 (2.13–32.69), and
7.89 (1.74–44.3) in Model 3. The alternate model, where
24-h U-P/eGFR, instead of 24-h U-P/CCr, was applied to a
variable, showed similar results (Table 4). TRP and eGFR
were correlated (r = 0.68, p < 0.001). However, neither
TRP nor TmP/GFR were associated with the composite
outcomes (data not shown). Moreover, the association be-
tween FeP and the outcome was observed in Model 1,
while in Models 2 and 3, higher FeP was not associated
with a higher risk for the outcomes.
Discussion
Our study showed that higher phosphorus excretion per
creatinine clearance was associated with CKD progres-
sion. This association remained after adjustment for
other possible risk factors related to CKD progression.
In a previous animal experiment, phosphate excretion
per nephron over 1 μg/day caused tubular damage [10]
while in another study, sevelamer hydrochloride, a phos-
phate binder, was renoprotective in rats [15]. In human
studies, high serum phosphorus was reported to be a
risk factor for CKD progression [4, 13, 16, 17], while
urinary phosphorus excretion has not been studied. This
is the first report to look for a possible association be-
tween urinary phosphorus excretion and CKD progres-
sion, although the underlying mechanism between high
phosphate excretion and CKD progression has not been
fully elucidated. High urine phosphorus may cause renal
tubular damage and renal fibrosis by forming calcium
phosphate crystals via oxidative stress [18]. A recent
cross-sectional analysis showed that TRP was associated
with eGFR [19]. In our study, TRP was associated with
eGFR, as previous studies reported [19, 20], but did not
show any relation to CKD progression. A previous study
showed no impact of FeP on CKD progression [21]. In
this study, patients were categorized according to FGF-
23 and FeP values. In our study, there was no adjust-
ment for FGF-23 because 24-h U-P/CCr would be a con-
founding factor for FGF-23. FGF23 cannot be measured
in clinical use in Japan so U-P/24 h-CCr may be a suit-
able surrogate marker.
U-P/24-h-CCr would be a confounding factor for
FGF23. A significant correlation was observed between
serum phosphorus and U-P/24-h-CCr in patients with
CKD stage G5, but not those with CKD stage G3b. In
early stage CKD, serum phosphorus was reported to re-
main in the normal range due to an increase in phos-
phorus excretion by FGF-23 [9, 22]. In addition, further
studies reported that elevated serum FGF-23 was associ-
ated with a decline in eGFR [23]. Therefore, early inter-
vention for phosphate restriction by lowering FGF-23
but not serum phosphorus levels was suggested as a new
strategy against CKD progression [9, 24, 25]. In such
cases, urinary phosphorus excretion per creatinine clear-
ance could be a useful marker for early intervention for
phosphate restriction because of its inexpensive and
minimally invasive features.
We applied 24-h CCr as a marker for nephron num-
bers, but eGFR is more commonly used by physicians.
Therefore, we also examined U-P/eGFR, instead of U-P/
24-h-CCr, as a marker for phosphorus burden to neph-
rons, and found similar reliability.
24-h U-P/CCr may be superior to 24-h U-P/eGFR for
the following reason. It is difficult to collect 24-h urine
Table 2 Distribution of events by quartiles of phosphorus
excretion per creatinine clearance
Composite end point ESKD 50 % reduction
of eGFR
All 90 50 40
Quartile 1 8 (8.9) 1 (2.0) 7 (17.5)
Quartile 2 18 (20.0) 5 (10.0) 13 (32.5)
Quartile 3 32 (35.6) 14 (28.0) 18 (45.0)
Quartile 4 32 (35.6) 30 (60.0) 2 (5.0)
Data are depicted as number of patients (% of total)
ESKD end-stage kidney disease, eGFR estimated glomerular filtration rate
Table 3 Hazard ratio (HR) and 95 % confidence interval (CI) of the composite outcome of end-stage kidney disease or 50 %
reduction of estimated glomerular filtration rate associated with urinary phosphorus excretion
Model 1 Model 2 Model 3
HR (95%CI) P Value HR (95%CI) P Value HR (95%CI) P Value
Quartile 1 1.00 1.00 1.00
(reference) (reference) (reference)
Quartile 2 2.56 0.02 1.66 0.31 3.07 0.057
(1.15–6.24) (0.63–4.97) (0.97–11.85)
Quartile 3 7.53 < 0.001 3.57 0.01 7.52 0.001
(3.63–17.62) (1.25–11.71) (2.13–32.69)
Quartile 4 12.17 < 0.001 5.34 0.01 7.89 0.006
(5.82–28.64) (1.41–22.32) (1.74–44.33)
Quartile 1 served as a reference. Model 2: Adjusted for age, male sex, diabetes mellitus, 24-h creatinine clearance, protein intake, urinary protein, corrected
calcium. Model 3: Adjusted for age, male sex, 24-h creatinine clearance, protein intake, corrected calcium, 1,25-dihydroxyvitamin D and intact parathormone
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accurately because of residual urine. The units of U-P/
24-h CCr and U-P/eGFR are presented as follows: (mg/
24 h)/(ml/min/24 h) and (mg/24 h)/(ml/min). If col-
lected urine is sampled only over 23 h, the value of U-P/
24-h CCr does not change greatly, because U-P and 24-h
CCr were collected during the same time. In this case,
the unit of U-P/24-h CCr is (mg/23 h)/(ml/min/23 h).
However, when normalizing eGFR, each urine sample
must be collected accurately over 24 h.
Study strengths and limitations
The strength of our study is that we included protein in-
take as a potential confounding factor. As a direct effect
of phosphate on the kidney, oral phosphate overload
damaged the kidney while oral phosphate restriction
prevented CKD progression in animals [26, 27]. How-
ever, it is certain that urinary phosphate is a surrogate
marker reflecting protein intake that is associated with
CKD progression [28]. Indeed, protein intake was corre-
lated with urinary phosphorus excretion in our study, but
not with 24-h U-P/CCr, which showed that 24-h U-P/CCr
is a risk factor independent of protein intake.
Another strength of our study was using 24-h col-
lected urine samples to measure urinary phosphorus ex-
cretion. Compared with spot urine, measuring 24-h
collected urine samples takes much time and effort. In
CKD patients, the circadian rhythm of urinary phos-
phorus excretion along with U-P/Cr/eGFR remains un-
clear, although urinary phosphorus excretion increases
from morning to the middle of the night in healthy sub-
jects [29].
Using 24-h collected urine can ensure more accurate
measurement of phosphorus excretion than spot urine.
However, spot urine could be an alternative prognostic
marker if the circadian change of U-P/Cr was resolved.
Our study has several limitations. First, it is a single-
center, retrospective observational study, and not an
interventional study, in a Japanese population. Second,
we mitigated the effect of confounding factors by using
multivariate Cox proportional hazard analysis. We ap-
plied PTH and 1,25(OH)VitD to the confounding vari-
ables in Model 3, but the sample size in each group may
have been insufficient for full evaluation.
Third, we assumed the number of nephrons was pro-
portionate to 24-h CCr, but the number of nephrons was
not fully proportionate to creatinine clearance. However,
a reliable marker for residual nephrons is not available
at present. Finally, we measured daily urinary phos-
phorus excretion only once even under the fixed menu
in admitted patients. Day to day variability in urinary
phosphorus excretion was not studied.
Conclusions
Our study showed that higher 24-h U-P/CCr was associ-
ated with more rapid CKD progression. Because an in-
crease of urinary phosphate excretion is reported to be
earlier than an elevation in serum phosphorus levels, 24-
h U-P/CCr may be a useful marker for suggesting phos-
phate burden to each nephron unit, thus enabling earlier
interventions. Further study is needed to resolve the
mechanism of 24-h U-P/CCr as a risk factor for CKD
progression.
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